Nevertheless, this finding could have important implications for recruitment into prevention trials for Alzheimer disease, which are increasingly incorporating presence of APOE-ε4 alleles into the inclusion criteria.29 If a trial is targeting disease clusters for dementia risk reduction, then the inclusion of noncarriers might be recommended. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.